|
US6682736B1
(en)
*
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7357928B2
(en)
*
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
|
SI1503794T1
(sl)
*
|
2002-04-12 |
2012-09-28 |
Medarex Inc |
Postopek zdravljenja z uporabo ctla-4 antiteles
|
|
KR101317045B1
(ko)
|
2002-09-06 |
2013-10-16 |
암젠 인코포레이티드 |
치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
|
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
KR101435167B1
(ko)
|
2003-06-27 |
2014-11-04 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
|
|
WO2005010048A2
(en)
|
2003-07-22 |
2005-02-03 |
Schering Aktiengesellschaft |
Rg1 antibodies and uses thereof
|
|
WO2005019270A2
(en)
*
|
2003-08-14 |
2005-03-03 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
EP1515505A1
(en)
*
|
2003-09-12 |
2005-03-16 |
Siemens Aktiengesellschaft |
Reachability maintainance of a moving network based on temporary name identifiers
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
AU2005209909B8
(en)
*
|
2004-02-03 |
2009-01-15 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
|
KR100845354B1
(ko)
*
|
2004-03-26 |
2008-07-09 |
화이자 프로덕츠 인코포레이티드 |
항－ｃｔｌａ－4 항체의 용도
|
|
US7785591B2
(en)
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
CA2586844A1
(en)
*
|
2004-11-04 |
2006-05-11 |
Pfizer Products Inc. |
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
|
|
NZ561137A
(en)
|
2005-03-08 |
2011-09-30 |
Pharmacia & Upjohn Co Llc |
Stable anti-CTLA-4 antibody compositions with chelating agents
|
|
WO2006101691A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
|
|
AU2006227880A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
|
|
MX2007013978A
(es)
*
|
2005-05-09 |
2008-02-22 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
|
|
NZ593388A
(en)
|
2005-06-08 |
2012-08-31 |
Dana Farber Cancer Inst Inc |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
|
|
CN101268101A
(zh)
*
|
2005-07-07 |
2008-09-17 |
科利制药集团公司 |
用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
|
|
NZ568016A
(en)
|
2005-12-07 |
2011-12-22 |
Medarex Inc |
CTLA-4 antibody dosage escalation regimens
|
|
EP2007423A2
(en)
*
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Ctla4 antibody combination therapy
|
|
WO2009016449A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Pfizer Limited |
Antibody purification process by precipitation
|
|
BRPI0817233A2
(pt)
|
2007-09-28 |
2012-11-06 |
Intrexon Corp |
construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
|
|
RU2373836C2
(ru)
*
|
2007-12-18 |
2009-11-27 |
Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" |
Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
|
|
US8449886B2
(en)
|
2008-01-08 |
2013-05-28 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
WO2011011027A1
(en)
*
|
2009-07-20 |
2011-01-27 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
RU2421217C2
(ru)
*
|
2009-09-03 |
2011-06-20 |
Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) |
Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
|
|
CA3019531A1
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
PT3446714T
(pt)
|
2011-06-02 |
2021-06-23 |
Univ Louisville Res Found Inc |
Nanopartículas conjugadas a um agente antinucleolina
|
|
CA2860941C
(en)
|
2012-03-13 |
2019-11-05 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of ovarian cancer
|
|
SG10201603896RA
(en)
|
2012-05-04 |
2016-07-28 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
EP2887959B1
(en)
*
|
2012-08-23 |
2018-12-19 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
|
DK2925350T3
(da)
*
|
2012-12-03 |
2019-05-13 |
Bristol Myers Squibb Co |
Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
|
|
KR20220148304A
(ko)
|
2013-08-08 |
2022-11-04 |
싸이튠 파마 |
병용 약학 조성물
|
|
HRP20231437T1
(hr)
|
2013-08-08 |
2024-02-16 |
Cytune Pharma |
Il-15 i il-15ralpha sushi domena na temelju modulokina
|
|
CA2926853C
(en)
*
|
2013-10-18 |
2022-04-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
|
EP3125938A4
(en)
*
|
2014-03-31 |
2017-08-23 |
The Johns Hopkins University |
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
|
|
JP6634625B2
(ja)
*
|
2014-05-01 |
2020-01-22 |
株式会社アネロファーマ・サイエンス |
異種ポリペプチド発現カセット
|
|
MX377844B
(es)
|
2014-05-28 |
2025-03-11 |
Agenus Inc |
Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
|
CA2964317C
(en)
|
2014-10-14 |
2021-10-05 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
JP6885867B2
(ja)
|
2014-12-31 |
2021-06-16 |
チェックメイト ファーマシューティカルズ， インコーポレイテッド |
組合せ腫瘍免疫療法
|
|
EP4151231A1
(en)
*
|
2015-02-13 |
2023-03-22 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
EP3291839A1
(en)
|
2015-05-05 |
2018-03-14 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
|
CN107849144B
(zh)
*
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
US9902772B2
(en)
*
|
2015-07-22 |
2018-02-27 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind LAG3
|
|
EP3337495A4
(en)
*
|
2015-08-18 |
2019-04-10 |
Mateon Therapeutics, Inc. |
USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods for using them
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
MA44483A
(fr)
|
2016-03-24 |
2019-01-30 |
Millennium Pharm Inc |
Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
EA039322B1
(ru)
*
|
2016-04-15 |
2022-01-13 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
JP7198666B2
(ja)
*
|
2016-08-26 |
2023-01-04 |
哲治 奥野 |
微小血管血流低減剤およびその利用
|
|
KR102504605B1
(ko)
*
|
2016-12-07 |
2023-03-02 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
CA3089768A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Oncoimmune, Inc. |
Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
WO2019179388A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel anti-ctla-4 antibody polypeptide
|
|
US12084655B2
(en)
|
2018-04-09 |
2024-09-10 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
SG11202100023XA
(en)
|
2018-07-11 |
2021-01-28 |
Actym Therapeutics Inc |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CN110092826B
(zh)
*
|
2019-02-28 |
2022-04-15 |
天津大学 |
CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
|
|
CN115803343A
(zh)
*
|
2020-05-26 |
2023-03-14 |
百奥泰生物制药股份有限公司 |
多特异性抗体及其应用
|
|
CN116113406B
(zh)
|
2020-07-10 |
2025-08-29 |
密歇根大学董事会 |
Gas41抑制剂及其使用方法
|
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
|
JP2024517131A
(ja)
|
2021-04-20 |
2024-04-19 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|